文章：

非小细胞肺癌KRAS突变靶向治疗的临床进展与挑战

Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer

原文发布日期：20 November 2024

DOI: 10.3390/cancers16223885

类型: Article

开放获取: 是

英文摘要：

KRAS mutation is one of the most common oncogenic drivers in non-small cell lung cancer. Since its discovery about four decades ago, drug development targeting KRAS has been met with countless failures. Recently, KRAS G12C, a subvariant of KRAS, became the first druggable KRAS mutation. The efficacy of the first-generation KRAS inhibitor is modest, but with scientific advancement, KRAS G12C inhibitors with higher potency are on the horizon. Additionally, novel therapeutic approaches targeting other KRAS subvariants are also being explored in clinical trials with encouraging early data. We will review the clinical advances and challenges for patients with KRAS-mutated non-small cell lung cancer, with a focus on small molecule inhibitors.

摘要翻译： 

KRAS突变是非小细胞肺癌中最常见的致癌驱动因素之一。自约四十年前被发现以来，针对KRAS的药物研发遭遇了无数失败。近期，KRAS亚型KRAS G12C成为首个可成药的KRAS突变。第一代KRAS抑制剂的疗效有限，但随着科学进步，更高效能的KRAS G12C抑制剂即将问世。此外，针对其他KRAS亚型的新型治疗方法也正在临床试验中探索，早期数据令人鼓舞。本文将重点围绕小分子抑制剂，综述KRAS突变非小细胞肺癌患者的临床进展与挑战。

原文链接：

Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer